Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FDD80
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,849
Award facts
- Contract value 100% obligated
- $6,848.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,848.92 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 ml auto-injector pharmaceutical product on October 27, 2025. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, and carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the work at its facility in Park Ridge, IL. This delivery order represents one of numerous awards the company has received from DLA's Medical Supply Chain division, reflecting its established capability to supply critical pharmaceuticals to Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR and valued at $499,999,999. The PPV-G GEN V represents a $30.3 billion acquisition strategy established to provide a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables, to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, awarded on November 13, 2025, includes a 30-month base period with three 30-month option periods extending through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting DoD pharmaceutical supply chain requirements globally.
Quick answers
Who was awarded contract SPE2DB26FDD80?
SPE2DB26FDD80 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FDD80 worth?
The government has obligated $6,849 on SPE2DB26FDD80.
Is contract SPE2DB26FDD80 an order under another contract?
Yes. SPE2DB26FDD80 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD80 competed?
The extent of competition for SPE2DB26FDD80 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award